TrialLancet (London, England)2017

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Toyoaki Hida et al.PubMed ↗Publisher ↗

No numbers read from the abstract.